[go: up one dir, main page]

PE20241063A1 - Composiciones y metodos para la inhibicion de ras - Google Patents

Composiciones y metodos para la inhibicion de ras

Info

Publication number
PE20241063A1
PE20241063A1 PE2024000129A PE2024000129A PE20241063A1 PE 20241063 A1 PE20241063 A1 PE 20241063A1 PE 2024000129 A PE2024000129 A PE 2024000129A PE 2024000129 A PE2024000129 A PE 2024000129A PE 20241063 A1 PE20241063 A1 PE 20241063A1
Authority
PE
Peru
Prior art keywords
alkyl
substituted
kras
unsubstituted
halogen
Prior art date
Application number
PE2024000129A
Other languages
English (en)
Inventor
Bin Wang
Rui Xu
Eli Wallace
Zuhui Zhang
David Michael Turner
Anna Elzbieta Maciag
Dhirendra Kumar Simanshu
Albert Hay Wah Chan
Ta Liao
Christopher John Brassard
Yue Yang
Paola Bisignano
Felice Lightstone
Original Assignee
Theras Inc
Leidos Biomedical Res Inc
L Livermore Nat Security Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Theras Inc, Leidos Biomedical Res Inc, L Livermore Nat Security Llc filed Critical Theras Inc
Publication of PE20241063A1 publication Critical patent/PE20241063A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/06—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Referido a un compuesto de formula IA, o una sal farmaceuticamente aceptable de este, en donde: R2 se selecciona de H, alquilo C1-6 y un carbociclo de 3-6 miembros; R3 se selecciona de alquilo C1-6 y un heterociclo de 4-6 miembros, R4 se selecciona de H, -OR12 y alquilo C1-6, donde cualquier alquilo C1-6 no esta sustituido o esta sustituido con uno o mas R13; R5 se selecciona de H, -CN, halogeno, alquilo C1-6, entre otros; R6 es un heteroarilo biciclico sustituido con uno o mas R15; R7 se selecciona de halogeno, -OR12, -CN y H; R8 se selecciona de H y alquilo C1-6, donde cualquier alquilo C1-6 no esta sustituido o esta sustituido con uno o mas R13. Estos compuestos son inhibidores de KRAS G12C dirigidos tanto a la proteina unida a GTP activa como a la proteina unida a GDP inactiva. Tambien se refiere a una composicion farmaceutica que comprende dicho compuesto y su uso en el tratamiento de una enfermedad como el cancer caracterizado por una mutacion KRAS G12C, tales como el cancer de pancreas, colorrectal y de pulmon.
PE2024000129A 2021-07-23 2022-07-22 Composiciones y metodos para la inhibicion de ras PE20241063A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163225407P 2021-07-23 2021-07-23
US202263329237P 2022-04-08 2022-04-08
PCT/US2022/037992 WO2023004102A2 (en) 2021-07-23 2022-07-22 Compositions and methods for inhibition of ras

Publications (1)

Publication Number Publication Date
PE20241063A1 true PE20241063A1 (es) 2024-05-13

Family

ID=82898940

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2024000129A PE20241063A1 (es) 2021-07-23 2022-07-22 Composiciones y metodos para la inhibicion de ras

Country Status (13)

Country Link
US (2) US20240300964A1 (es)
EP (1) EP4373822A2 (es)
JP (1) JP2024526949A (es)
KR (1) KR20240052096A (es)
AU (1) AU2022315228A1 (es)
CA (1) CA3227138A1 (es)
CL (1) CL2024000201A1 (es)
CO (1) CO2024000588A2 (es)
IL (1) IL310291A (es)
MX (1) MX2024001108A (es)
PE (1) PE20241063A1 (es)
TW (1) TW202315610A (es)
WO (1) WO2023004102A2 (es)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023205701A1 (en) 2022-04-20 2023-10-26 Kumquat Biosciences Inc. Macrocyclic heterocycles and uses thereof
JP2023540270A (ja) 2020-08-28 2023-09-22 カムクワット バイオサイエンシーズ インコーポレイテッド 複素環式化合物およびその使用
WO2023004102A2 (en) 2021-07-23 2023-01-26 Theras, Inc. Compositions and methods for inhibition of ras
TW202334138A (zh) 2021-11-05 2023-09-01 美商新領域醫藥公司 癌症治療方法
WO2023137223A1 (en) * 2022-01-17 2023-07-20 Newave Pharmaceutical Inc. Pan-kras inhibitors and uses thereof
CN118660891A (zh) * 2022-02-14 2024-09-17 深圳福沃药业有限公司 作为kras g12c突变抑制剂的喹唑啉衍生物
CN119136806A (zh) 2022-03-08 2024-12-13 锐新医药公司 用于治疗免疫难治性肺癌的方法
WO2023172737A1 (en) 2022-03-11 2023-09-14 Kumquat Biosciences Inc. Heterocyclic compounds and uses thereof
JP2025510656A (ja) * 2022-03-24 2025-04-15 ベイジーン スウィッツァーランド ゲーエムベーハー 複素環式化合物、その組成物、及びそれらを用いた治療方法
JP2025517125A (ja) * 2022-05-04 2025-06-03 カムクワット バイオサイエンシーズ インコーポレイテッド 複素環式化合物及びその使用
JP2025521232A (ja) 2022-06-10 2025-07-08 レボリューション メディシンズ インコーポレイテッド 大環状ｒａｓ阻害剤
WO2023246777A1 (en) * 2022-06-20 2023-12-28 Jacobio Pharmaceuticals Co., Ltd. K-ras mutant protein inhibitors
IL318748A (en) * 2022-08-05 2025-04-01 Theras Inc Compositions and methods for inhibiting KRAS
KR20250060956A (ko) 2022-08-05 2025-05-07 컴쿼트 바이오사이언시즈 인크. 헤테로환 화합물 및 이의 용도
WO2024083246A1 (en) * 2022-10-21 2024-04-25 Ascentage Pharma (Suzhou) Co., Ltd. Kras inhibitors
EP4655298A1 (en) * 2023-01-24 2025-12-03 Theras Inc. Compositions and methods for inhibition of ras
CN116178284A (zh) * 2023-02-24 2023-05-30 重庆医药高等专科学校 一种2,4-二羟基喹唑啉及其衍生物的合成方法
EP4687905A1 (en) 2023-03-30 2026-02-11 Revolution Medicines, Inc. Compositions for inducing ras gtp hydrolysis and uses thereof
WO2024211663A1 (en) 2023-04-07 2024-10-10 Revolution Medicines, Inc. Condensed macrocyclic compounds as ras inhibitors
EP4688790A1 (en) 2023-04-07 2026-02-11 Revolution Medicines, Inc. Macrocyclic ras inhibitors
KR20250169290A (ko) 2023-04-14 2025-12-02 레볼루션 메디슨즈, 인크. Ras 억제제의 결정형, 이를 함유하는 조성물 및 이의 사용 방법
KR20250172857A (ko) 2023-04-14 2025-12-09 레볼루션 메디슨즈, 인크. Ras 억제제의 결정형
CN118834160B (zh) * 2023-04-23 2025-12-19 中国医学科学院药物研究所 Ubrelvy关键手性内酰胺中间体及其衍生物的不对称合成方法
WO2024229406A1 (en) 2023-05-04 2024-11-07 Revolution Medicines, Inc. Combination therapy for a ras related disease or disorder
CN121464141A (zh) * 2023-06-29 2026-02-03 海思科医药集团股份有限公司 一种5元杂芳基衍生物及其在医药上的应用
WO2025034702A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Rmc-6291 for use in the treatment of ras protein-related disease or disorder
TW202525800A (zh) * 2023-09-08 2025-07-01 大陸商泰勵生物科技（上海）有限公司 Ｒａｓ抑制劑
WO2025080589A1 (en) * 2023-10-09 2025-04-17 Incyte Corporation Processes for preparing kras inhibitors
US20250154171A1 (en) 2023-10-12 2025-05-15 Revolution Medicines, Inc. Ras inhibitors
WO2025117828A1 (en) * 2023-12-01 2025-06-05 Theras, Inc. Compositions and methods for inhibition of ras
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
WO2025255438A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013155223A1 (en) 2012-04-10 2013-10-17 The Regents Of The University Of California Compositions and methods for treating cancer
EP3401314B1 (en) 2013-03-15 2023-11-08 Araxes Pharma LLC Covalent inhibitors of kras g12c
CA2926328C (en) * 2013-10-10 2022-11-29 Araxes Pharma Llc Substituted quinazolinyl and quinolinyl derivatives and pharmaceutical compositions thereof useful as inhibitors of kras g12c
TWI659021B (zh) 2013-10-10 2019-05-11 亞瑞克西斯製藥公司 Ｋｒａｓ ｇ１２ｃ之抑制劑
JO3556B1 (ar) 2014-09-18 2020-07-05 Araxes Pharma Llc علاجات مدمجة لمعالجة السرطان
US10011600B2 (en) 2014-09-25 2018-07-03 Araxes Pharma Llc Methods and compositions for inhibition of Ras
EA201792214A1 (ru) 2015-04-10 2018-01-31 Араксис Фарма Ллк Соединения замещенного хиназолина
KR20180081596A (ko) 2015-11-16 2018-07-16 아락세스 파마 엘엘씨 치환된 헤테로사이클릭 그룹을 포함하는 2-치환된 퀴나졸린 화합물 및 이의 사용 방법
US9988357B2 (en) 2015-12-09 2018-06-05 Araxes Pharma Llc Methods for preparation of quinazoline derivatives
WO2017172979A1 (en) 2016-03-30 2017-10-05 Araxes Pharma Llc Substituted quinazoline compounds and methods of use
AU2018271990A1 (en) 2017-05-25 2019-12-12 Araxes Pharma Llc Covalent inhibitors of KRAS
EP3630747A1 (en) 2017-05-25 2020-04-08 Araxes Pharma LLC Quinazoline derivatives as modulators of mutant kras, hras or nras
AR116604A1 (es) * 2018-10-15 2021-05-26 Lilly Co Eli Inhibidores de kras g12c
IL311187B1 (en) 2018-11-09 2025-11-01 Hoffmann La Roche Process for the synthesis of fused cyclic chemical compounds and intermediates therefor
WO2020146613A1 (en) 2019-01-10 2020-07-16 Mirati Therapeutics, Inc. Kras g12c inhibitors
CN112110918B (zh) 2019-06-21 2023-08-22 劲方医药科技(上海)有限公司 螺环取代的嘧啶并环类化合物，其制法与医药上的用途
CN114980976A (zh) 2019-11-27 2022-08-30 锐新医药公司 共价ras抑制剂及其用途
EP4083042A4 (en) 2019-12-27 2024-07-31 Wigen Biomedicine Technology (Shanghai) Co., Ltd. SPIRO-RING-CONTAINING QUINAZOLINE COMPOUND
WO2021218110A1 (zh) * 2020-04-29 2021-11-04 上海凌达生物医药有限公司 一类苯并噻唑基联芳基类化合物、制备方法和用途
CN113754653A (zh) * 2020-06-05 2021-12-07 明慧医药（上海）有限公司 一种kras g12c抑制剂化合物及其用途
CN115836055A (zh) 2020-06-30 2023-03-21 益方生物科技(上海)股份有限公司 喹唑啉化合物、其制备方法和用途
CN113880827B (zh) 2020-07-03 2024-10-01 苏州闻天医药科技有限公司 一种用于抑制krasg12c突变蛋白的化合物及其制备方法和用途
JP2023540270A (ja) 2020-08-28 2023-09-22 カムクワット バイオサイエンシーズ インコーポレイテッド 複素環式化合物およびその使用
US20230081426A1 (en) 2020-09-18 2023-03-16 Plexxikon Inc. Compounds and methods for kras modulation and indications therefor
WO2022068921A1 (zh) 2020-09-30 2022-04-07 上海医药集团股份有限公司 一种喹唑啉类化合物及其应用
TW202227441A (zh) 2020-10-21 2022-07-16 大陸商貝達藥業股份有限公司 喹唑啉化合物、包含其的藥物組合物及其應用
CA3199082A1 (en) 2020-10-27 2022-05-05 Amgen Inc. Heterocyclic spiro compounds and methods of use
WO2022105855A1 (en) 2020-11-20 2022-05-27 Jacobio Pharmaceuticals Co., Ltd. Kras g12d inhibitors
TWI880049B (zh) 2020-12-04 2025-04-11 美商美國禮來大藥廠 Kras g12c抑制劑
TWI894413B (zh) 2020-12-22 2025-08-21 大陸商上海科州藥物股份有限公司 作為ｋｒａｓ抑制劑的雜環化合物的製備及其應用方法
CN113999226B (zh) * 2020-12-22 2023-01-06 上海科州药物研发有限公司 作为kras抑制剂的杂环化合物的制备及其应用方法
WO2022148422A1 (en) 2021-01-08 2022-07-14 Beigene, Ltd. Bridged compounds as kras g12d inhibitor and degrader and the use thereof
WO2022156792A1 (en) 2021-01-25 2022-07-28 Guangdong Newopp Biopharmaceuticals Co., Ltd. Heterocyclic compounds as sos1 inhibitors
CA3209083A1 (en) * 2021-02-16 2022-08-25 Theras, Inc. Compositions and methods for inhibition of ras
WO2022251576A1 (en) 2021-05-28 2022-12-01 Merck Sharp & Dohme Corp. Small molecule inhibitors of kras g12c mutant
CN115433179A (zh) 2021-06-03 2022-12-06 正大天晴药业集团股份有限公司 苯并嘧啶类化合物及其医药用途
CN117500799A (zh) 2021-06-09 2024-02-02 伊莱利利公司 作为kras g12d抑制剂的取代的稠合吖嗪
WO2023004102A2 (en) 2021-07-23 2023-01-26 Theras, Inc. Compositions and methods for inhibition of ras
WO2023018699A1 (en) 2021-08-10 2023-02-16 Erasca, Inc. Selective kras inhibitors
AR128211A1 (es) 2022-01-06 2024-04-10 Theras Inc Composiciones y métodos para la inhibición de ras
US20250188085A1 (en) 2022-01-06 2025-06-12 Theras, Inc. Compositions and methods for inhibition of ras
WO2023141300A1 (en) 2022-01-20 2023-07-27 Kumquat Biosciences Inc. Heterocyclic compounds and uses thereof
WO2023150284A2 (en) 2022-02-03 2023-08-10 Mirati Therapeutics, Inc. Quinazoline pan-kras inhibitors
JP2025510656A (ja) 2022-03-24 2025-04-15 ベイジーン スウィッツァーランド ゲーエムベーハー 複素環式化合物、その組成物、及びそれらを用いた治療方法
JP2025517125A (ja) 2022-05-04 2025-06-03 カムクワット バイオサイエンシーズ インコーポレイテッド 複素環式化合物及びその使用
WO2023225252A1 (en) 2022-05-20 2023-11-23 Theras, Inc. Compositions and methods for inhibition of ras
IL318748A (en) 2022-08-05 2025-04-01 Theras Inc Compositions and methods for inhibiting KRAS
US20260035376A1 (en) 2022-08-05 2026-02-05 Theras, Inc. Compositions and methods for inhibition of ras
EP4655298A1 (en) 2023-01-24 2025-12-03 Theras Inc. Compositions and methods for inhibition of ras
WO2025117828A1 (en) 2023-12-01 2025-06-05 Theras, Inc. Compositions and methods for inhibition of ras

Also Published As

Publication number Publication date
IL310291A (en) 2024-03-01
CL2024000201A1 (es) 2024-06-14
CA3227138A1 (en) 2023-01-26
MX2024001108A (es) 2024-04-05
KR20240052096A (ko) 2024-04-22
JP2024526949A (ja) 2024-07-19
WO2023004102A3 (en) 2023-03-02
AU2022315228A1 (en) 2024-02-08
CO2024000588A2 (es) 2024-04-18
US12528818B2 (en) 2026-01-20
US20240300964A1 (en) 2024-09-12
TW202315610A (zh) 2023-04-16
WO2023004102A2 (en) 2023-01-26
US20250270225A1 (en) 2025-08-28
EP4373822A2 (en) 2024-05-29

Similar Documents

Publication Publication Date Title
PE20241063A1 (es) Composiciones y metodos para la inhibicion de ras
PE20230249A1 (es) Compuestos de heteroarilo biciclicos y usos de estos
PE20220141A1 (es) Inhibidores de la proteina tirosina fosfatasa
SA522433155B1 (ar) مركبات ثلاثية الحلقة مستبدلة
PE20230825A1 (es) Inhibidores de kras triciclicos fusionados
PE20220931A1 (es) Inhibidores de shp2 fosfatasa de tipo pirazolo[3,4-b]pirazina
AR040971A1 (es) Compuestos pirimido que tienen actividad antiproliferativa
EA201891191A1 (ru) 2-замещенные соединения хиназолина, содержащие замещенную гетероциклическую группу, и способы их применения
PE20191817A1 (es) Tienopiridinas y benzotiofenos utiles como inhibidores de cinasa 4 asociada al receptor de interleucina 1 (irak4)
AR116604A1 (es) Inhibidores de kras g12c
PE20241129A1 (es) Inhibidores de parp1 de azetidina y pirrolidina y usos de estos
EA201890594A1 (ru) Арильные, гетероарильные и гетероциклические соединения для лечения заболеваний
PE20191613A1 (es) Compuestos de pirazolo[1,5-a]piridina sustituidos como inhibidores de la quinasa ret
PE20190912A1 (es) Compuesto de piridona como inhibidor de c-met
EA201891553A1 (ru) Ингибиторы syk
EA202092168A1 (ru) Применение фавипиравира в лечении коронавирусной инфекции
NO20065148L (no) Monocykliske heterocykler som kinase inhibitorer
PE20170677A1 (es) Nuevos compuestos como inhibidores de reorganizado durante la transfeccion (ret)
PE20170127A1 (es) Indazol-3-carboxamidas 5-sustituidas y preparacion y uso de las mismas
EA201000947A1 (ru) Производные тиазола, применимые в качестве ингибиторов киназы pi3
EA201290260A1 (ru) Бензимидазол-имидазольные производные
AR055592A1 (es) Derivados de 2-amino-5-cicloalquil-hidantoina como moduladores y/o inhibidores de la beta-secretasa(bace)
EA201692249A1 (ru) Ингибиторы фосфатидилинозитол-3-киназы
PE20091556A1 (es) Derivado heterociclico fusionado y su uso
EA201692266A1 (ru) Ингибиторы фосфатидилинозитол-3-киназы